NYSE:PFE
Pfizer Inc (PFE)
Financials 
Technical Analysis 
Jun 24, 2026, 12:00 amThis summary was created by AI, based on 29 opinions in the last 12 months.
Pfizer Inc (PFE) is facing significant challenges as it navigates a patent cliff and the subsequent impacts on revenue after its COVID-19 vaccine boom. Many analysts express concerns about the lack of earnings momentum and the uncertain prospects for new blockbuster drugs in its pipeline. Despite these challenges, PFE maintains an attractive dividend yield ranging from 6% to 7% that provides a steady income for shareholders. The company's strategy includes cost-cutting measures and acquiring smaller companies to refill its drug development pipeline. However, the stock typically trades at a low price-to-earnings ratio, indicating a lack of confidence in future growth, with multiple experts suggesting a need for patience and a potential wait for positive catalysts to drive price appreciation.
Pfizer vs. JNJ
That just bought a company, and he immediately thought of the 2008 Wyeth acquisition (at the top of that cycle), and right after shares plunged. Pfizer's timing has not improved. Better to buy JNJ which is doing spin-offs that should benefit the company. JNJ is well-managed and regularly raises its dividend.
Prefers ABBV. Main overhang to PFE is what happens to the vaccine franchise now that we're on the other side of Covid? PFE will need other engines, it's a show-me story. ABBV is a leader in immunology. Humira is coming off patent, which will compress earnings, but that's well-known by the market. Its pipeline will fill the gap, plus Botox business.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentWe reiterate PFE as a TOP PICK. With a ROE of 36% and trading at 7x earnings this is good value here. The company expects to hear soon if its RSV vaccine will get approval as one of the first available for people over 60 years of age. Cash reserves continue growing while the company retires debt. It pays a nice dividend, backed by a payout ratio un 30% of cash flow. We continue to recommend a stop-loss at $35, looking to achieve $52.50 - upside potential over 28%. Yield 3.9%
(Analysts’ price target is $52.52)
Good cash flow and pays a 3.7x dividend. Cheap at 12x PE. Good cardio drug in the pipeline, looking promising. Shares are down lately because of a general rotation and society is getting indifferent to Covid and vaccines. Management sees 7-9% revenue growth outside Covid vaccines. Strong balance sheet. Offers defence and offence.
Stan Wong
Premium contentStan WongStan Wong'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Would hold shares with ~4% dividend yield.
Believes demand for drugs will continue despite Covid-19 ending.
Demand for healthcare will continue to rise.
Current share price is over sold.
P/E ratio at 6x very attractive.